These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2006-001871-39||A PHASE II, MULTI CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, DOSE-ESCALATION, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF CK-1827452 IN PATIENTS WITH STABLE HEART FAILURE.||2009-02-12||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-004987-23||A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)||2014-03-21||bad-data|
|Reported results||2014-005413-23||A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic ...||2017-09-27||due-trials|
|Reported results||2016-002629-13||A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031)||2018-10-26||due-trials|
|Reported results||2018-000586-37||A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosi...||2019-03-07||due-trials|
|Ongoing||2019-002785-12||A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic h...||not-yet-due|